We herewith a press release titled Extract of Audited Standalone and Consolidated financial Results of the Quarter and Year Ended March''31,2026 for your kind information and record.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 16.6 pts less than Nifty Microcap 250 and 17.4 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Asarfi Hospital Limited reported strong FY26 results with revenue growing 42% YoY to ₹117.3 Cr, driven by a 45% increase in IPD revenue and 14% growth in OPD revenue. The company achieved an EBITDA margin of 20% and PAT margin of 10%, supported by improved ARPOB (Average Revenue Per Patient) of ₹23,020 for super-specialty and ₹37,428 for cancer unit. Growth was led by high-acuity specialties like Cardiology, Neurology, and Orthopaedics, along with improved traction in Radiation Oncology at the cancer unit. The audited results were reviewed by the Audit Committee and approved by the Board of Directors on May 11, 2026.
The strong 42% revenue growth and improved profitability margins indicate operational efficiency gains and successful specialty mix enhancement. The healthy PAT margin of 10% and robust IPD/OPD volume growth suggest sustained demand for the company's healthcare services, which could positively influence investor sentiment.